FCA
APLS

FinTrust Capital Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

FinTrust Capital Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5
Closed – – 1206
2022
Q1 		$0 Hold
5
– – ﹤0.01% 1213
2021
Q4 		$0 Buy
+5
New +$197 ﹤0.01% 1181

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FinTrust Capital Advisors's APLS Position: Q2 2022 in Review

FinTrust Capital Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2022, closing a stake of 5 shares.

FinTrust Capital Advisors first reported a position in APLS in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 211 funds tracked by Wall St. Rank hold APLS as of Q2 2022.

  • FinTrust Capital Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • FinTrust Capital Advisors sold 5 Apellis Pharmaceuticals shares in Q2 2022.
  • FinTrust Capital Advisors first reported a position in Apellis Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • FinTrust Capital Advisors's Apellis Pharmaceuticals position peaked at $0 in Q1 2022.
  • 211 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2022.

Based on FinTrust Capital Advisors's 13F filing for Q2 2022, filed 26 Jul 2022.